Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Recommendation of "Moderate Buy" by Brokerages
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) have earned a consensus rating of "Moderate Buy" from the eleven research firms that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $59.22.
據MarketBeat Ratings報道,箭頭製藥公司(納斯達克代碼:ARWR-GET Rating)的股票已被目前涵蓋該股票的11家研究公司的共識評級為“適度買入”。三位研究分析師對該股的評級為持有建議,六位分析師對該公司發出了買入建議。在過去一年發佈該股報告的分析師中,平均一年目標價為59.22美元。
Several research firms recently commented on ARWR. SVB Leerink cut their price target on Arrowhead Pharmaceuticals from $33.00 to $31.00 and set a "market perform" rating on the stock in a research note on Tuesday, November 29th. Chardan Capital cut their price target on Arrowhead Pharmaceuticals from $82.00 to $60.00 in a research note on Tuesday, January 10th. Piper Sandler cut their price target on Arrowhead Pharmaceuticals from $64.00 to $55.00 in a research note on Monday, January 9th. The Goldman Sachs Group reiterated a "buy" rating and issued a $66.00 price target (up previously from $65.00) on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 30th. Finally, Jefferies Financial Group cut their price target on Arrowhead Pharmaceuticals from $92.00 to $75.00 and set a "buy" rating on the stock in a research note on Tuesday, November 29th.
幾家研究公司最近對ARWR發表了評論。SVB Leerink在11月29日(星期二)的一份研究報告中將箭頭製藥的目標價從33.00美元下調至31.00美元,並對該股設定了“市場表現”評級。Chardan Capital在1月10日星期二的一份研究報告中將箭頭製藥的目標價從82.00美元下調至60.00美元。派珀·桑德勒在1月9日週一的一份研究報告中將他們對箭頭製藥的目標價從64.00美元下調至55.00美元。11月30日,週三,高盛在一份研究報告中重申了買入評級,並對箭頭製藥的股票發佈了66.00美元的目標價(之前的目標價為65.00美元)。最後,傑富瑞金融集團在11月29日星期二的一份研究報告中,將箭頭製藥的目標價從92.00美元下調至75.00美元,並對該股設定了“買入”評級。
Insider Buying and Selling at Arrowhead Pharmaceuticals
箭頭製藥公司的內幕買賣
In other Arrowhead Pharmaceuticals news, Director William D. Waddill sold 3,200 shares of the company's stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $30.00, for a total transaction of $96,000.00. Following the sale, the director now owns 28,950 shares in the company, valued at $868,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director William D. Waddill sold 3,200 shares of the stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $30.00, for a total transaction of $96,000.00. Following the sale, the director now directly owns 28,950 shares in the company, valued at approximately $868,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Martin Javier San sold 19,500 shares of the stock in a transaction that occurred on Monday, November 21st. The stock was sold at an average price of $29.99, for a total value of $584,805.00. Following the sale, the insider now owns 91,500 shares in the company, valued at $2,744,085. The disclosure for this sale can be found here. Insiders have sold 109,966 shares of company stock worth $4,050,435 over the last quarter. 3.20% of the stock is owned by corporate insiders.
在其他箭頭製藥公司的消息中,董事威廉·D·沃迪爾在1月9日星期一的一筆交易中出售了3,200股該公司股票。該股以30.00美元的平均價格出售,總成交金額為9.6萬美元。交易完成後,董事現在擁有該公司28,950股股份,價值868,500美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可在這個環節。其他消息方面,董事威廉·D·沃迪爾在1月9日(星期一)的一筆交易中出售了3200股該公司股票。該股以30.00美元的平均價格出售,總成交金額為9.6萬美元。交易完成後,董事現在直接持有該公司28,950股股份,價值約868,500美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可以通過美國證券交易委員會網站。此外,內部人士馬丁·哈維爾·桑在11月21日星期一的一筆交易中出售了19,500股該股。這隻股票的平均售價為29.99美元,總價值為584,805.00美元。出售後,這位內部人士現在擁有該公司91,500股,價值2,744,085美元。關於這次銷售的披露可以找到這裏。在上個季度,內部人士已經出售了109,966股公司股票,價值4,050,435美元。3.20%的股份由企業內部人士持有。
Institutional Trading of Arrowhead Pharmaceuticals
箭頭藥品的機構性交易
Arrowhead Pharmaceuticals Price Performance
箭頭藥品價格表現
Shares of NASDAQ ARWR opened at $36.82 on Tuesday. Arrowhead Pharmaceuticals has a 1-year low of $26.81 and a 1-year high of $58.96. The business has a 50-day moving average of $33.74 and a 200-day moving average of $36.71. The company has a market capitalization of $3.90 billion, a price-to-earnings ratio of -21.92 and a beta of 1.26.
週二,納斯達克arwr的股價開盤報36.82美元。箭頭製藥的一年低點為26.81美元,一年高位為58.96美元。該業務的50日移動均線切入位在33.74美元,200日移動均線切入位在36.71美元。該公司市值為39億美元,市盈率為-21.92倍,貝塔係數為1.26。
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last issued its earnings results on Monday, November 28th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.24). Arrowhead Pharmaceuticals had a negative return on equity of 40.23% and a negative net margin of 71.01%. The company had revenue of $31.58 million during the quarter, compared to analysts' expectations of $107.60 million. Research analysts expect that Arrowhead Pharmaceuticals will post -0.59 EPS for the current fiscal year.
箭頭製藥(納斯達克:ARWR-GET評級)最近一次發佈財報是在11月28日(星期一)。這家生物技術公司公佈了本季度每股收益(0.81美元),低於普遍預期的(0.57美元)和(0.24美元)。箭頭製藥的淨資產收益率為負40.23%,淨利潤率為負71.01%。該公司本季度營收為3158萬美元,高於分析師預期的1.076億美元。研究分析師預計,箭頭製藥公司本財年的每股收益將為0.59美元。
About Arrowhead Pharmaceuticals
關於箭頭製藥公司
(Get Rating)
(獲取評級)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis.
箭頭製藥公司在美國開發治療頑固性疾病的藥物。該公司正在籌備中的產品包括用於治療與α-1抗胰蛋白酶缺乏相關的肝病的候選RNA幹擾(RNAi)藥物ARO-AAT,處於第二階段臨牀試驗的ARO-APOC3,處於2b期和治療高甘油三酯血癥的第三階段臨牀試驗的ARO-APOC3,治療血脂異常的2b期臨牀試驗的ARO-ANG3,用於治療肝病的第1/2期臨牀試驗的ARO-HSD,用於治療血脂異常囊性纖維化的臨牀前階段的ARO-ENaC2;ARO-C3,用於減少補體成分3的產生,處於第1/2a期臨牀試驗;ARO-DUX4,用於治療面部肩臂肌營養不良,處於臨牀前階段;ARO-XDH,用於治療不受控制的痛風;ARO-COV,處於治療新冠肺炎的臨牀前階段;ARO-RAGE,用於治療粘液阻塞性或炎症性肺部疾病,處於1/2a期臨牀試驗;以及ARO-MMP7,處於1/2期臨牀試驗,用於治療特發性肺纖維化。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Arrowhead Pharmaceuticals (ARWR)
- Why Warner Bros Discovery Is the S&P's Hottest Stock
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- Pinterest is the Social Commerce Platform to Watch in 2023
- 4 High-Yield Dividend Kings For 2023
- Will 2023 be a Good Year for Goodyear Tire Stock?
- 免費獲取StockNews.com關於箭頭製藥的研究報告(ARWR)
- 為什麼華納兄弟探索成為標準普爾最熱門的股票
- 沃爾格林靴子聯盟的收益低於預期對投資者有利嗎?
- Pinterest是2023年值得關注的社交商務平臺
- 2023年4大高收益股利之王
- 2023年對固特異輪胎庫存來説會是一個好年份嗎?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受《箭頭藥業日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對箭頭製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。